Therapeutic Development Services

SCHEDULE A CONSULTATION

At BlueRidge Life Sciences (BRLS), we help biotech and pharmaceutical companies bring promising neurological therapies from early discovery to clinical reality. With a specialization in neurology, psychiatric and central nervous system (CNS) disorders, our team combines scientific rigor, clinical insight, and regulatory expertise to design and execute trials that are built to succeed the first time.

Our approach centers on smarter, more efficient study designs including asking the right questions early and reducing risk throughout the development process. From preclinical review to regulatory strategy and medical oversight, every engagement is led by senior physicians and scientists who ensure every study is credible, compliant, and ready for regulatory scrutiny. With BRLS, you gain a trusted ally to advance your program with clarity, speed, and confidence.

OUR CLINICAL DEVELOPMENT & REGULATORY AFFAIRS SERVICES

BRLS provides end-to-end clinical development support for neurological, psychiatric and rare disease programs. From preclinical assessment through regulatory submission, our experts help clients design smarter studies, strengthen scientific rationale, and navigate complex regulatory landscapes with confidence. Each engagement is tailored to accelerate progress while maintaining the highest standards of scientific and operational excellence.

  • We help clients evaluate the strength of their scientific foundation before entering the clinic. Deliverables include: 

    • Review of existing preclinical efficacy, safety, and PK/PD data 

    • Recommendations for additional studies to support IND submission 

    • Translational strategies linking animal data to human endpoints 

    Result: A strong, defensible preclinical package that de-risks the transition to clinical phases. 

  • Our team develops integrated roadmaps that guide a therapeutic candidate from preclinical to pivotal trials. Deliverables include: 

    • Comprehensive development plan with milestones and risk assessments 

    • Go/no-go decision frameworks 

    • Alignment of R&D, regulatory, and business objectives 

    Result: A cohesive plan that accelerates development and minimizes costly missteps. 

  • We design and manage trials that are scientifically sound and operationally efficient. Deliverables include:

    • Design first in human, early Proof Of Concept (POC), and adequate and well controlled trials with focus on inclusion/exclusion, endpoint selection, statistical principles

    • Draft clinical protocols and statistical analysis plans (SAP)

    • Site and investigator selection recommendations

    • Anomalous data monitoring

    • Enrollment Authorization Committees to ensure suitable subject selection to reduce variability

    • Set-up and Management of Data Safety Monitoring Boards (DSMB)

    • Assist in the selection of appropriate Contract Research Organization (CRO), including creation of the Request for proposal (RFP), CRO vetting via services and budget review and the bid defense process.

    Result: Studies designed for success — credible, compliant, and ready for regulatory review. 

  • Our regulatory experts, including 3 former division directors in the Division of Neurology Products at FDA, help teams navigate complex global regulatory issues and agency interactions with confidence. Deliverables include:

    • Regulatory pathway assessments for FDA and Ex-US regulatory authorities

    • Support for Type A, B (pre-IND, EOP2, pre-NDA, etc), C and D meetings with FDA, including drafting and reviewing briefing documents and in person meeting participation.

    • Support for Ex-US regulatory interactions, including strategic planning, review of briefing package and attendance at meetings

    • Reviews of informational requests, safety updates and label language

    • IND/CTA, NDA  Document review

    • Clinical hold strategic support

    • Novel regulatory pathway expertise

    Result: A smoother regulatory journey and stronger likelihood of approval to proceed.

  • We craft clear, accurate, and persuasive scientific and clinical documentation tailored to neurological, psychiatric, and CNS indications. Deliverables include:

    • Protocols, Investigator Brochures, Clinical Study Reports, and manuscripts

    • Expert input on clinical rationale and statistical interpretation

    Result: Submission- and publication-ready materials that communicate your science with precision and impact. 

  • We provide independent assessments and expert insights to guide partnerships and investments. Deliverables include: 

    • Data room review

    • Evaluation of clinical data packages

    • Risk-benefit assessments and expert opinion reports

    Result: Informed decisions grounded in scientific and regulatory reality. 

  • Access strategic medical leadership without the cost of a full-time executive. Deliverables include: 

    • Fractional or interim CMO support 

    • Oversight of clinical and regulatory activities  

    • Representation in investor and board of director meetings

    Result: Senior-level leadership that strengthens programs and accelerates development. 

CAPABILITIES THAT SET US APART

BRLS combines the precision of academic neuroscience with the practical speed of industry execution. Our approach isn’t just about running trials, it’s about designing smarter ones that are statistically sound, operationally efficient, and regulatory-ready from the start.

Every engagement is led by senior clinicians who have personally designed and overseen pivotal CNS studies, ensuring science and strategy remain tightly aligned from early development through regulatory review.

With BRLS, you gain a collaborative partner who understands the complexities of CNS drug development and delivers results that stand up to scientific and regulatory scrutiny.

WHO WE SUPPORT

BRLS partners with biotech, pharmaceutical companies, and investors to advance neurological, psychiatric and CNS therapies from early research to late-stage development.

  • Small to mid-sized biotech and pharmaceutical organizations developing novel therapies for neurological, psychiatric, and CNS disorders often rely on BRLS to:

    • Design smarter, more efficient clinical trials

    • Avoid costly protocol or regulatory missteps

    • Accelerate programs toward IND or pivotal Phase 3 readiness

  • Academic medical centers, venture-backed startups, and investors focused on neurodegenerative, psychiatric, or pain indications benefit from our ability to: 

    • Conduct independent due diligence and feasibility reviews 

    • Provide expert medical guidance for translational programs 

    • Support asset preparation for partnership or acquisition 

Ready to Strengthen Your Clinical Development Strategy?

Contact us today to assess your clinical program and learn how BlueRidge Life Sciences can help you design smarter trials, reduce risk, and accelerate your path to approval.

Schedule a consultation